Oral semaglutide improved liver health, diabetes status, and lipid profile in patients with MASLD and T2D, with weight loss ...

People with type 2 diabetes who use semaglutide drugs like Ozempic and Wegovy appear to have a lower risk of Alzheimer's ...

Researchers have found that semaglutide may lower the risk of Alzheimer's disease in people with type 2 diabetes (T2D).

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of ...

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...

People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared ...

For patients with type 2 diabetes (T2D), duodenal recellularization via electroporation therapy (ReCET), which uses pulsed ...

Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a ...

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with ...

The GLP-1 RA semaglutide was associated with a 40%-70% reduced risk for first-time diagnosis of AD in patients with type 2 diabetes, real-world data show.

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...